CardioWise Reports Development of Method for Detection of Heart Disease
National Science Foundation grants totaling $180,000 supported company's workTuesday, January 14, 2014
FAYETTEVILLE, Ark. — CardioWise Inc. has submitted its final report to the National Science Foundation that detailed its continued development and commercialization of a non-invasive analysis method for detection of heart disease.
CardioWise is a portfolio company of VIC Technology Venture Development, a privately held firm based at the Arkansas Research and Technology Park in Fayetteville. The University of Arkansas Technology Development Foundation manages the park.
CardioWise received two grants totaling $180,000 through the NSF’s Small Business Innovation Research Program, which allows federal agencies to stimulate technological innovation in the private sector by strengthening small businesses that meet federal research and development needs. The program also is intended to increase the commercial application of federally supported research results.
The final report submitted to the NSF in December detailed the research and development milestones that were achieved during the 2013 award period including:
- Development and testing of cloud-based software as a service solution that supports upload of magnetic resonance images to CardioWise for analysis, and download of CardioWise analysis to any browser-based device in compliance with the Health Insurance Portability and Accountability Act and Certified Electronic Health Record Technology. This allows the analysis to be sent to any mobile device so that providers, doctors and patients can see and understand the diagnosis and actively participate in decisions about treatment.
- Automation and testing of software components of the MRI analysis currently being done by hand reducing total analysis time from six hours to less than 30 minutes, allowing the entire image acquisition and analysis to be completed in a single office visit.
- Clinical validation testing of the CardioWise analysis software on separate MRI scans acquired on the same patient on the same MRI, as well as scans acquired on the same patient but on different MRI systems. This validation is important for regulatory submission and clearance and also to insure patient safety.
The CardioWise analysis software is uniquely capable of analyzing the 3-D motion of the heart that is acquired from cardiac MRI images and then comparing the analysis at 15,300 points to the motion of a normal heart model. The analysis detects portions of the heart that are moving abnormally and demonstrates to what degree the heart muscle has been affected. Since MRI uses no ionizing radiation or contrast, it is completely non-invasive and poses no risk to the patient. This diagnostic analysis method may aid doctors to determine what intervention, such as surgery, stent insertion, or drug is most appropriate for the patient who presents with cardiovascular disease symptoms.
CardioWise analysis software is a platform technology that can analyze heart contractile motion from other imaging modalities just as well as images acquired from MRI systems. In cardiac ultrasound (echocardiogram) and computerized tomographic (CT) images wall motion, recognizable patterns and easily identifiable cardiac anatomy may be tracked to produce input to CardioWise for analysis. The company’s long-term strategy is to address all of these available markets with its platform analysis product.
Miriam Hudson-Courtney, communications manager
VIC Technology Venture Development
Chris Branam, research communications writer/editor